{"component": "definition", "props": {"groups": [{"samples": [{"hash": "kD8m6W1FHt8", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?991+ful+HB1819H1+pdf", "label": "legacylis.virginia.gov", "score": 18.2345180511, "published": false}, {"hash": "jqqYLpueQSd", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?961+ful+SB34S1+pdf", "label": "legacylis.virginia.gov", "score": 18.2345180511, "published": false}, {"hash": "6Vhqizlt3Rl", "uri": "https://legacylis.virginia.gov/cgi-bin/legp604.exe?971+ful+SB1190+pdf", "label": "legacylis.virginia.gov", "score": 17.9384098053, "published": false}], "size": 60, "snippet": "means the taking of two or more ingredients and fabricating them into a single", "snippet_links": [], "hash": "d766edd2e64f87fbb539a6e972bac962", "id": 1}, {"samples": [{"hash": "3VqkNTldWRC", "uri": "/contracts/3VqkNTldWRC#compound", "label": "Agreement of Coverage", "score": 28.1062068939, "published": true}, {"hash": "aAHZnN98OfW", "uri": "/contracts/aAHZnN98OfW#compound", "label": "Epo Agreement of Coverage", "score": 26.835729599, "published": true}, {"hash": "2nipX0p8ghd", "uri": "/contracts/2nipX0p8ghd#compound", "label": "Agreement of Coverage", "score": 26.835729599, "published": true}], "size": 46, "snippet": "means to form or create a Medically Necessary customized composite product by combining two (2) or more different ingredients according to a Physician\u2019s specifications to meet an individual patient\u2019s need.", "snippet_links": [{"key": "medically-necessary", "type": "definition", "offset": [26, 45]}, {"key": "according-to", "type": "definition", "offset": [126, 138]}, {"key": "an-individual", "type": "clause", "offset": [176, 189]}], "hash": "40ff46fceb03b8fd2f070b4666bc9211", "id": 2}, {"samples": [{"hash": "9uAozd7afCt", "uri": "/contracts/9uAozd7afCt#compound", "label": "Research Collaboration Agreement (ArriVent BioPharma, Inc.)", "score": 35.86926651, "published": true}, {"hash": "bLQKtSbDx2T", "uri": "/contracts/bLQKtSbDx2T#compound", "label": "Research Collaboration Agreement (ArriVent Biopharma, Inc.)", "score": 35.0095825195, "published": true}, {"hash": "cqepFxHXj6a", "uri": "/contracts/cqepFxHXj6a#compound", "label": "Research Collaboration Agreement (ArriVent Biopharma, Inc.)", "score": 34.9274482727, "published": true}], "size": 33, "snippet": "means [***].", "snippet_links": [], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 3}, {"samples": [{"hash": "9UKSM6MoXOX", "uri": "/contracts/9UKSM6MoXOX#compound", "label": "License Agreement", "score": 33.493347168, "published": true}, {"hash": "8BTiZcAhKvm", "uri": "/contracts/8BTiZcAhKvm#compound", "label": "License Agreement", "score": 33.2059211731, "published": true}, {"hash": "gi8YtayxFOM", "uri": "/contracts/gi8YtayxFOM#compound", "label": "License Agreement", "score": 33.1758117676, "published": true}], "size": 29, "snippet": "means (1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2-oxopyrrolidin- 3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3- azabicyclo[3.1.0]hexane-2-carboxamide, which has the molecular formula C23H32F3N5O4 and having the structure to be set forth on Appendix 1 attached hereto, as referred to internally by Pfizer as PF-07321332. For clarity, \u201cCompound\u201d includes all forms of (1R,2S,5S)-N-{(1S)-1-Cyano-2-[(3S)-2- oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]- 3-azabicyclo[3.1.0]hexane-2-carboxamide, including but not limited to, isomers, stereoisomers, diastereomers, tautomers, hydrates, solvates, crystal forms including crystalline forms and co-crystalline forms, amorphous forms, polymorphs, metabolites and prodrugs thereof. Additionally, \u201cCompound\u201d includes all deuterated forms.", "snippet_links": [{"key": "appendix-1", "type": "definition", "offset": [255, 265]}, {"key": "by-pfizer", "type": "clause", "offset": [309, 318]}, {"key": "for-clarity", "type": "clause", "offset": [335, 346]}, {"key": "not-limited", "type": "clause", "offset": [555, 566]}], "hash": "4dbac8283618729900792cd4e1086f04", "id": 4}, {"samples": [{"hash": "cR9lvBBAGKI", "uri": "/contracts/cR9lvBBAGKI#compound", "label": "Definitions for Chapter", "score": 26.699508667, "published": true}, {"hash": "J29hC99fb5", "uri": "/contracts/J29hC99fb5#compound", "label": "Definitions for Chapter", "score": 17.5057029724, "published": true}, {"hash": "aBuTk24L1u8", "uri": "https://apps.legislature.ky.gov/record/09RS/hb297/bill.doc", "label": "apps.legislature.ky.gov", "score": 8.4483232498, "published": false}], "size": 28, "snippet": "or \"compounding\" means the preparation or labeling of a drug pursuant to or in anticipation of a valid prescription drug order including, but not limited to, packaging, intravenous admixture or manual combination of drug ingredients. \"Compounding,\" as used in this chapter, shall not preclude simple reconstitution, mixing, or modification of drug products prior to administration by nonpharmacists;", "snippet_links": [{"key": "pursuant-to", "type": "clause", "offset": [61, 72]}, {"key": "in-anticipation-of", "type": "definition", "offset": [76, 94]}, {"key": "prescription-drug-order", "type": "definition", "offset": [103, 126]}, {"key": "not-limited", "type": "clause", "offset": [142, 153]}, {"key": "intravenous-admixture", "type": "definition", "offset": [169, 190]}, {"key": "this-chapter", "type": "definition", "offset": [260, 272]}, {"key": "modification-of", "type": "clause", "offset": [327, 342]}, {"key": "drug-products", "type": "definition", "offset": [343, 356]}, {"key": "prior-to", "type": "clause", "offset": [357, 365]}], "hash": "be5fd7828e39c8dcab9127f0cc97cce3", "id": 5}, {"samples": [{"hash": "ef5Slpx7vwc", "uri": "https://apps.legislature.ky.gov/recorddocuments/bill/24RS/sb27/bill.pdf", "label": "apps.legislature.ky.gov", "score": 15.9122858047, "published": false}, {"hash": "5Xi2k3l6Hq2", "uri": "https://apps.legislature.ky.gov/recorddocuments/bill/24RS/SB27/SCS1.pdf", "label": "apps.legislature.ky.gov", "score": 15.84416008, "published": false}, {"hash": "dYSREQ06GZt", "uri": "https://apps.legislature.ky.gov/recorddocuments/bill/24RS/hb806/orig_bill.pdf", "label": "apps.legislature.ky.gov", "score": 15.7817811966, "published": false}], "size": 13, "snippet": "or \"compounding\" means the preparation or labeling of a drug", "snippet_links": [], "hash": "1a280d0e87014e448f0a070aed9ce4af", "id": 6}, {"samples": [{"hash": "gtDGZyY9a53", "uri": "https://lis.virginia.gov/cgi-bin/legp604.exe?961+ful+CHAP0152+pdf", "label": "lis.virginia.gov", "score": 11.308008194, "published": false}, {"hash": "bpZ2dOcMBF6", "uri": "https://lis.virginia.gov/cgi-bin/legp604.exe?031+ful+CHAP0509+pdf", "label": "lis.virginia.gov", "score": 11.2819986343, "published": false}, {"hash": "9FTMrobfd1B", "uri": "https://lis.virginia.gov/cgi-bin/legp604.exe?031+ful+CHAP0995+pdf", "label": "lis.virginia.gov", "score": 11.2121829987, "published": false}], "size": 12, "snippet": "means the taking of two or more ingredients and fabricating them into a single preparation, usually referred to as a dosage form.", "snippet_links": [{"key": "dosage-form", "type": "definition", "offset": [117, 128]}], "hash": "cfd8f7c9a8f568046fcbed5750546a87", "id": 7}, {"samples": [{"hash": "68S373CJgzz", "uri": "/contracts/68S373CJgzz#compound", "label": "Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 32.8384666443, "published": true}, {"hash": "jIVDMjaL1N", "uri": "/contracts/jIVDMjaL1N#compound", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7816562653, "published": true}, {"hash": "aHrGezSDAKR", "uri": "/contracts/aHrGezSDAKR#compound", "label": "Research, Development and Commercialization Agreement (Royalty Pharma PLC)", "score": 31.7433261871, "published": true}], "size": 11, "snippet": "means a chemical compound, including salts and prodrugs thereof, which is synthesized and/or tested by or under the direction of VERTEX or its Affiliates during the term of the Research Program under this Agreement, or which was synthesized and/or tested by and/or under the direction of Aurora or its Affiliates under the Original Agreement; which is either a Potentiator or a Corrector, or both; and which [***]", "snippet_links": [{"key": "chemical-compound", "type": "definition", "offset": [8, 25]}, {"key": "by-or-under-the-direction-of", "type": "definition", "offset": [100, 128]}, {"key": "term-of-the-research-program", "type": "clause", "offset": [165, 193]}, {"key": "this-agreement", "type": "clause", "offset": [200, 214]}, {"key": "the-original-agreement", "type": "clause", "offset": [319, 341]}], "hash": "3b5203ab7da9bc12d294070158b7f97b", "id": 8}, {"samples": [{"hash": "hNHKIxYRP10", "uri": "/contracts/hNHKIxYRP10#compound", "label": "License Agreement (CPEX Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "f9b7dvoFxy9", "uri": "/contracts/f9b7dvoFxy9#compound", "label": "License Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "eb5fv4w3rv6", "uri": "/contracts/eb5fv4w3rv6#compound", "label": "License Agreement (Auxilium Pharmaceuticals Inc)", "score": 21.0, "published": true}], "size": 11, "snippet": "is defined above in the Recitals.", "snippet_links": [{"key": "defined-above", "type": "clause", "offset": [3, 16]}, {"key": "the-recitals", "type": "clause", "offset": [20, 32]}], "hash": "101eb9d13dc646a90ee1d04a2b0f62fa", "id": 9}, {"samples": [{"hash": "lygC3wnBpfq", "uri": "https://docs.legis.wisconsin.gov/statutes/statutes/450.pdf", "label": "docs.legis.wisconsin.gov", "score": 9.5065021515, "published": false}, {"hash": "gmdGCKTXWlS", "uri": "https://docs.legis.wisconsin.gov/2017/statutes/statutes/450.pdf", "label": "docs.legis.wisconsin.gov", "score": 7.6557154655, "published": false}, {"hash": "bhZBPQL9xR1", "uri": "https://docs.legis.wisconsin.gov/2015/statutes/statutes/450.pdf", "label": "docs.legis.wisconsin.gov", "score": 5.5044488907, "published": false}], "size": 11, "snippet": "means to mix, combine or put together vari- ous ingredients or drugs for the purpose of dispensing.", "snippet_links": [{"key": "for-the-purpose-of", "type": "definition", "offset": [69, 87]}], "hash": "0489377a6f28727d9130fafeebc693ed", "id": 10}], "next_curs": "ClUST2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjELEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIRY29tcG91bmQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"size": 2971, "title": "Compound", "snippet": "means the taking of two or more ingredients and fabricating them into a single", "id": "compound", "examples": ["Kissei shall be responsible for all costs incurred by it in non-clinical and clinical development activities related to <strong>Compound</strong> and Product in the Kissei Territory.", "Kissei shall have the royalty-free, non-exclusive right and license to use all of the Vogenx Know-How (including the patents obtained thereon) resulting from the activities undertaken by Vogenx, its Affiliate and its sublicensees, if any, pursuant to this Agreement, and to disclose and sublicense the same to Kissei\u2019s Affiliates and licensee(s), if any, for the sole purpose of manufacture, develop, use or sale of the <strong>Compound</strong> or the Product (but not a Combination Product) in the Kissei Territory.", "In the event that any unexpected or unusual findings including adverse drug reactions are found during the course of the development by either Vogenx or Kissei and their respective Affiliate(s) or its sublicensee(s), if any, of the <strong>Compound</strong> or the Product, each Party shall [***]inform the other Party of such findings and, where necessary, both Parties hereto shall discuss the matter [***].", "Kissei hereby grants to Vogenx an exclusive license, with the right to grant sublicenses, under the Kissei Patents and the Kissei Know-How to make, have made and use the <strong>Compound</strong> in the Field in the Vogenx Territory, and to make, have made, use, sell, offer to sell and import the Product in the Field in the Vogenx Territory.", "Upon expiration of this Agreement, Vogenx will continue to have a royalty-free, perpetual right to continue to make, have made, use, sell, offer to sell and import the <strong>Compound</strong> and the Products.", "Such Vogenx rights shall be limited solely to the development, formulation, manufacture, use, sale, or import of the <strong>Compound</strong>, the Products (including Combination Products) in the Field in the Vogenx Territory.", "Kissei and Vogenx shall execute a separate agreement within [***] to mutually exchange material information on the <strong>Compound</strong> and the Product relating to, among other things, the safety thereof including adverse drug reactions.", "Each Party shall promptly notify the other Party by telephone or facsimile as soon as it learns of any inquiry, contact or communication received from or sent to any regulatory agency, which relates in any way to the <strong>Compound</strong> or the Product, and shall promptly furnish the other Party with copies of all such communications to the extent available.", "Kissei and Vogenx shall each promptly inform the other in writing with respect to any significant information it comes to know of (from any source) relating in any way to the safety or efficacy of the <strong>Compound</strong> or Product including possible adverse drug reactions.", "Vogenx shall be responsible for all costs incurred by it in non-clinical and clinical development activities related to <strong>Compound</strong> and Product in the Vogenx Territory."], "related": [["licensed-compound", "Licensed Compound", "Licensed <strong>Compound</strong>"], ["collaboration-compound", "Collaboration Compound", "Collaboration <strong>Compound</strong>"], ["lead-compound", "Lead Compound", "Lead <strong>Compound</strong>"], ["compounds", "Compounds", "<strong>Compounds</strong>"], ["licensed-compounds", "Licensed Compounds", "Licensed <strong>Compounds</strong>"]], "related_snippets": [], "updated": "2026-07-18T04:26:07+00:00"}, "json": true, "cursor": ""}}